Diuretic therapy in acute heart failure;Tratamiento con diuréticos en la insuficiencia cardíaca aguda

Medicina Clinica

Volumn 142, Issue SUPPL. 1, 2014, Pages 36-41

  Carles Trullàs, Joan ^a   Morales Rull, José Luis ^b   Formiga, Francesc ^c  

^a UNIVERSITY OF GIRONA   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Congestive heart failure; Diuretics; Furosemide; Heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SODIUM;

ACUTE HEART FAILURE; ARTICLE; DIURETIC THERAPY; ELECTROLYTE BLOOD LEVEL; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; KIDNEY FUNCTION; NEPHRON; SODIUM ABSORPTION; ACUTE DISEASE; ADSORPTION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; HEMODYNAMICS; KIDNEY TUBULE; METABOLISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; ADSORPTION; DIURETICS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUROSEMIDE; HEART FAILURE; HEMODYNAMICS; HUMANS; KIDNEY TUBULES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84902976360     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(14)70081-8     Document Type: Article

References (33)

1. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725-36.
2. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003:4 Suppl 7:S2-30.
3. Von Lueder TG, Atar D, Krum H. Diuretic use in heart failure and outcomes. Clin Pharmacol Ther. 2013;94:490-8.
4. Gottlieb SS. Management of volume overload in heart failure. En: Heart Failure: A Companion to Braunwalds Heart Disease. 2nd ed. St. Louis: Elsevier Saunders; 2011. p. 650-8.
5. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2:CD003838.
6. Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynne J, Mills RM, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113:12-9.
7. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.
8. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJ. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973;288:1087-90.
9. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
10. Flórez J, Armijo JA. Fármacos diuréticos. En: Flórez J, Armijo JA, Mediavilla A, editores. Farmacología humana. 5.a ed. Barcelona: Masson; 2008. p. 931-43.
11. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102:314-8.
12. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocar dial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-35.
13. Veeraveedu PT, Watanabe K, Ma M, Thandavarayan RA, Palaniyandi SS, Yamaguchi K, et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol. 2008;75:649-59.
14. Cosín J, Díez J; TORIC investigatos. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-13.
15. Konecke LL. Clinical trial of bumetanide versus furosemide in patients with congestive heart failure. J Clin Pharmacol. 1981;21:688-90.
16. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM, et al. Openlabel randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-20.
17. Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother. 2009;43:1836-47.
18. Salvador DRK, Rey NR, Ramos GC, Punzalan FER. Infusión continua versus inyección en bolo de diuréticos de asa para la insuficiencia cardíaca congestiva (Revisión Cochrane traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley and Sons, Ltd.). En: La Biblioteca Cochrane Plus, 2008 Nmero 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com
19. Shah RV, McNulty S, OConnor CM, Felker GM, Braunwald E, Givertz MM. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Am Heart J. 2012;164:862-8.
20. Trulls JC, Morales-Rull JL, Formiga F. Diuretic therapy in heart failure. Med Clin (Barc). 2013; Doi:pii: S0025-7753(13)00311-4. [Epub ahead of print].
21. Jentzer JC, DeWald TA, Hernández AF. Combination of loop diuretics with thiazidetype diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527-34.
22. Dormans TP, Gerlag PG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J. 1996;17:1867-74.
23. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71:146-50.
24. Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure (CLOROTIC). ClinicalTrials.gov Identifier: NCT01647932. Disponible en: www.clinicaltrials. gov
25. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-7.
26. Pitt B, Remme W, Zannad F, Neaton J, Martínez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
27. Zannad F, McMurray JJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
28. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2:370-6.
29. Van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71:21A-8A.
30. Hensen J, Abraham WT, Drr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11:441-6.
31. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med. 2013 Sep 23; Doi:pii: S0953-6205(13)00921-7. [Epub ahead of print].
32. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-319.
33. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33: 1787-847.